A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and Neupogen in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy

Trial Profile

A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and Neupogen in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Febrile neutropenia
  • Focus Registrational; Therapeutic Use
  • Acronyms PIONEER
  • Sponsors Sandoz
  • Most Recent Events

    • 28 Oct 2017 Results assessing the efficacy for pooled switched groups to the unswitched reference group (excluding patients who received biosimilar filgrastim alone continuously) during cycles 2-6, published in the Annals of Oncology Journal.
    • 06 Jun 2017 Results assessing safety profile of EP2006 from this and other EU registration trial (n=277) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results comparing pooled switched groups to the unswitched reference group for efficacy presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top